Literature DB >> 9664144

Cytotoxic effects of sphingolipids as single or multi-modality agents on human melanoma and soft tissue sarcoma in vitro.

E Auzenne1, M E Leroux, M Hu, R E Pollock, B Feig, J Klostergaard.   

Abstract

We evaluated the cytotoxic effects of a cell-permeable ceramide (Cer), N-hexanoyl-D-sphingosine (C6-Cer) and of two related sphingoid bases, sphingosine (So) and dihydrosphingosine (sphinganine; Sa) on human melanoma cell lines and on soft tissue sarcoma lines recently established from fresh surgical biopsy specimens. These cell lines ranged from high susceptibility (939 melanoma) to strong resistance (A2058 melanoma and all three sarcomas) to tumour necrosis factor (TNF), an inducer of elevated intracellular Cer levels. However, all the cell lines demonstrated a dose-dependent susceptibility to C6-Cer with protracted cytotoxic kinetics, with the C8161 melanoma being the most sensitive and A2058 the least. Protein kinase C (PKC) antagonizes Cer-dependent apoptosis, and chelerythrine chloride, So and Sa, which inhibit PKC, caused extremely rapid cytotoxicity of melanoma cell lines, irrespective of their relative sensitivity to C6-Cer. So-mediated cytotoxicity was extensive even after only 90 min of treatment, within the time frame of limb perfusion. So and Sa only slightly potentiated the cytotoxic responses to TNF, C6-Cer or melphalan. Sphingolipid-driven intracellular pathways may offer opportunities for therapy of these tumours.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9664144     DOI: 10.1097/00008390-199806000-00005

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  5 in total

1.  C-6 Ceramide Induces p53 Dependent Apoptosis in Human Astrocytoma Grade4 (Glioblastoma Multiforme) Cells.

Authors:  Hirendra Nath Banerjee; Millon Blackshear; Jordan Williams; Zack Hawkins; Crystal Sawyer; Vinod Manglik; Shailendra Giri
Journal:  J Cancer Sci Ther       Date:  2012-02-01

Review 2.  Protein kinase C targeting in antineoplastic treatment strategies.

Authors:  W D Jarvis; S Grant
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.

Authors:  Jacqueline V Chapman; Valérie Gouazé-Andersson; Ramin Karimi; Maria C Messner; Myles C Cabot
Journal:  Exp Cell Res       Date:  2011-03-21       Impact factor: 3.905

4.  Enigmol: a novel sphingolipid analogue with anticancer activity against cancer cell lines and in vivo models for intestinal and prostate cancer.

Authors:  Holly Symolon; Anatoliy Bushnev; Qiong Peng; Harsha Ramaraju; Suzanne G Mays; Jeremy C Allegood; Sarah T Pruett; M Cameron Sullards; Dirck L Dillehay; Dennis C Liotta; Alfred H Merrill
Journal:  Mol Cancer Ther       Date:  2011-03-11       Impact factor: 6.261

5.  Targeted Metabolomics Identifies Plasma Biomarkers in Mice with Metabolically Heterogeneous Melanoma Xenografts.

Authors:  Daniela D Weber; Maheshwor Thapa; Sepideh Aminzadeh-Gohari; Anna-Sophia Redtenbacher; Luca Catalano; René G Feichtinger; Peter Koelblinger; Guido Dallmann; Michael Emberger; Barbara Kofler; Roland Lang
Journal:  Cancers (Basel)       Date:  2021-01-23       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.